Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients

Diagnostic Microbiology and Infectious Disease

Volumn 39, Issue 1, 2001, Pages 25-31

  Wong Beringer, Annie ^a   Hindler, Janet ^b   Brankovic, illiana ^b   Muehlbauer, Lisa ^c   Steele Moore, Lynn ^c  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Christiana Care Infectious Disease Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; PYRROLE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; CANDIDIASIS; CHILD; CROSS RESISTANCE; DRUG EXPOSURE; FEMALE; FUNGEMIA; HOSPITAL INFECTION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; AZOLES; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; FUNGEMIA; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035122008     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(00)00209-1     Document Type: Article

References (13)

1. The epidemiology of hematogenous candidiasis caused by different Candida species
2. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: Results from a multicenter prospective study of candidemia
3. The changing face of Candidemia: Emergence of non-Candida albicans species and antifungal resistance
4. Do in vitro susceptibility data predict microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia
5. National surveillance of nosocomial bloodstream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program
6. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States
7. Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia
8. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
9. The contribution of fluconazole to the changing epidemiology of invasive candidal infections
10. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
11. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind multicenter trial
12. Treatment of funguria